Hyoscyamus Niger 6c

Hyoscyamus Niger 6c Manufacturers

• Paramesh Banerji Life Sciences Llc
  

  ×

  Hyoscyamus Niger 6c | Solco Healthcare Us, Llc

  

  ---

  2.1 General Considerations

  The side effects of irbesartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. [See Adverse Reactions (6).]

  Maximum antihypertensive effects are attained within 2 to 4 weeks after a change in dose.

  Irbesartan and Hydrochlorothiazide Tablets may be administered with or without food.

  Irbesartan and Hydrochlorothiazide Tablets may be administered with other antihypertensive agents.

  Renal impairment. The usual regimens of therapy with Irbesartan and Hydrochlorothiazide Tablets may be followed as long as the patient’s creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so Irbesartan and Hydrochlorothiazide Tablets are not recommended.

  Hepatic impairment. No dosage adjustment is necessary in patients with hepatic impairment.

  2.2 Add-On Therapy

  In patients not controlled on monotherapy with irbesartan or hydrochlorothiazide, the recommended doses of Irbesartan and Hydrochlorothiazide Tablets, in order of increasing mean effect, are (irbesartan-hydrochlorothiazide) 150/12.5 mg, 300/12.5 mg, and 300/25 mg. The largest incremental effect will likely be in the transition from monotherapy to 150/12.5 mg. [See Clinical Studies (14.2).]

  2.3 Replacement Therapy

  Irbesartan and Hydrochlorothiazide Tablets may be substituted for the titrated components.

  2.4 Initial Therapy

  The usual starting dose is Irbesartan and Hydrochlorothiazide Tablets 150/12.5 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of 300/25 mg once daily as needed to control blood pressure [see Clinical Studies (14.2)]. Irbesartan and Hydrochlorothiazide Tablets are not recommended as initial therapy in patients with intravascular volume depletion [see Warnings and Precautions (5.2)].

  Close
  No Recall

  More Info